greeksoup/ stock research

Utah Medical Products (UTMD) Q3 FY2026 earnings: revenue $9 million, down 12.1% on the year

Utah Medical Products Inc. (UTMD) reported revenue of $9 million for Q3 FY2026, the quarter ended 30 September 2026, down 12.1% on the same quarter a year earlier. Net income was $3 million, up 5.9% on the year, and diluted earnings per share $0.88. The figures are the company's own, from the 10-Q it filed with the SEC on 13 November 2026.

Revenue
$9 million
-12.1% on the year · +1.1% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
32.4%
26.6% a year earlier
Q4 FY2024Q3 FY2026
Net income
$3 million
+5.9% on the year · +3.8% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$0.88
+7.3% on the year · +4.8% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised, 1 new.

  • Revenue fell 12% in quarter: Third-quarter revenue was $8,621, down $1,191 (12.1%); nine-month revenue was $25,873, down $3,602 (12.1%).
  • Operating income rose in quarter: Third-quarter operating income was $2,795, up 7.0%, with a 32.4% margin against 26.6%. Nine-month operating income was $8,009, down 10.6%.
  • Filshie sales fell sharply in quarter: Worldwide Filshie sales fell $805 (32.7%) in the quarter, with domestic Filshie sales $534 lower. Nine-month Filshie sales were $1,194 (15.7%) lower.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue8.68.59.8+1.1%-12.1%
Cost of revenue3.83.84.2+0.3%-10.1%
Gross profit4.84.85.6+1.7%-13.6%
Gross margin56.1%55.8%57.1%
Research and development0.10.20.2-7.8%-15.0%
Selling, general and administrative1.92.02.8-2.7%-32.7%
Operating income2.82.62.6+5.5%+7.0%
Operating margin32.4%31.1%26.6%
Pre-tax income3.43.33.3+3.5%+2.8%
Income tax0.60.60.7+2.3%-9.4%
Effective tax rate18.1%18.3%20.5%
Net income2.82.72.6+3.8%+5.9%
Net margin32.3%31.5%26.8%
Diluted EPS$0.88$0.84$0.82+4.8%+7.3%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow3.51.43.9+153.1%-9.7%
Capital expenditure0.20.10.0+76.1%+774.1%
Free cash flow3.31.23.9+161.3%-15.2%
Free cash flow margin37.9%14.6%39.2%
Cash from investing-4.3-0.1-0.0
Cash from financing-1.6-1.1-1.6
Depreciation and amortisation0.30.20.8+11.9%-66.4%
Share-based compensation0.10.10.1+6.9%-18.1%
Buybacks0.70.10.7+796.2%+7.0%
Dividends paid1.01.01.00.0%-0.1%
Diluted shares, weighted3m3m3m-0.1%-0.8%
Shares outstanding at period end3m3m3m-0.3%-0.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity123122118+1.0%+4.3%
Non-controlling interestn/a0.0n/a
Debt0.20.20.2-7.7%-25.3%
Other liabilities5.02.33.5+115.2%+44.8%
Total liabilities and equity129125122+3.2%+5.4%
Fixed assets10.09.610.0+4.1%+0.2%
Goodwill14.014.014.1+0.0%-0.6%
Intangible assets3.90.31.4+1,022.5%+179.0%
Cash and equivalents85.287.584.3-2.7%+1.1%
Receivables4.03.63.7+11.1%+6.3%
Inventory10.69.08.1+17.4%+30.2%
Other assets0.90.50.4+65.4%+112.8%
Total assets129125122+3.2%+5.4%

Questions

What was Utah Medical Products' revenue in Q3 FY2026?

Utah Medical Products (UTMD) reported revenue of $9 million for Q3 FY2026, the quarter ended 30 September 2026, down 12.1% on the same quarter a year earlier.

How much did Utah Medical Products earn in Q3 FY2026?

Net income for Q3 FY2026 was $3 million, up 5.9% on the year, and diluted earnings per share $0.88.

When did Utah Medical Products report Q3 FY2026 results?

Utah Medical Products filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 13 November 2026.

Quarterly results, the last 20 quarters

Q4 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue12.912.313.413.013.612.512.912.512.311.310.410.09.29.710.09.89.08.78.58.6
Cost of revenue4.84.85.34.85.24.75.15.15.24.64.14.23.84.24.44.23.83.43.83.8
Gross profit8.17.58.28.28.37.87.77.47.16.86.35.85.35.55.65.65.35.34.84.8
Gross margin63%61%61%63%61%63%60%59%58%60%60%58%58%57%56%57%58%61%56%56%
R&D0.10.10.10.10.10.10.10.10.10.30.30.20.10.20.10.20.20.20.20.1
SG&An/a2.93.02.9n/a3.33.23.3n/a2.62.62.3n/a2.22.32.8n/a2.62.01.9
Operating income5.14.55.15.15.14.44.44.03.93.93.43.32.93.23.22.62.42.62.62.8
Operating margin40%37%38%40%37%35%34%32%32%34%33%33%32%32%32%27%27%29%31%32%
Pre-tax income5.24.55.25.35.65.15.24.85.04.84.24.23.63.93.83.33.13.23.33.4
Tax rate20%22%21%20%19%18%19%18%15%18%18%15%20%21%21%20%17%18%18%18%
Net income4.13.54.14.34.64.24.23.94.34.03.53.62.93.03.02.62.62.62.72.8
Net margin32%29%31%33%34%34%33%31%35%35%33%36%32%31%31%27%28%30%31%32%
Diluted EPS$1.13$0.96$1.12$1.18$1.25$1.16$1.15$1.08$1.18$1.09$0.98$1.02$0.86$0.92$0.94$0.82$0.80$0.82$0.84$0.88
Operating cash flow5.05.04.85.65.76.94.95.15.35.32.83.92.94.52.93.93.53.11.43.5
Capital expenditure0.30.20.20.30.00.00.30.20.10.00.10.10.00.20.10.00.10.10.10.2
Free cash flow4.74.84.65.35.66.94.64.95.25.32.73.82.94.32.83.93.43.01.23.3
Buybacks0.0n/an/a0.0n/a0.00.00.00.03.06.43.96.73.23.50.71.00.10.10.7
Dividends paid8.30.01.11.11.11.11.11.11.11.11.11.11.01.01.01.01.01.01.01.0
Shares outstanding4m4m4m4m4m4m4m4m4m4m3m3m3m3m3m3m3m3m3m3m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 13 November 2026: the filing.